 |
| |||
| ||||
|
| |||
|
| ||||
| |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
No | Ctr | Title | PubDate | Int.Class | Appl.No | Applicant | Inventor | ||||
| 1. | US | 20130095146 - CICLESONIDE CONTAINING AQUEOUS PHARMACEUTICAL COMPOSITION | 18.04.2013 |
| 13688659 | NYCOMED GmbH | NAGANO Atsuhiro | ||||
An aqueous pharmaceutical composition which comprises ciclesonide, crystalline cellulose carmellose sodium and hydroxypropylmethylcellulose is provided. | |||||||||||
| 2. | US | 20130096152 - NOVEL SALTS OF 6-HETEROCYCLE SUBSTITUTED HEXAHYDROPHENANTHRIDINE DERIVATIVES | 18.04.2013 |
| 13707969 | NYCOMED GMBH | KAUTZ Ulrich | ||||
Disclosed herein are salts of 6-heteroaryl substituted hexahydrophenanthridine PDE4 inhibiting compounds, which can be used in the pharmaceutical industry for the production of pharmaceutical compositions. | |||||||||||
| 3. | WO | WO/2013/053937 - A DEPROTEINISED CALF BLOOD PREPARATION FOR USE IN PREVENTION OR TREATMENT OF POST-STROKE COGNITIVE IMPAIRMENT | 18.04.2013 |
| PCT/EP2012/070375 | NYCOMED AUSTRIA GMBH | VIGONIUS, Ulf | ||||
The present invention relates to a deproteinised calf blood preparation for use in the prevention or treatment of post-stroke cognitive impairment, wherein the deproteinised calf blood preparation is administered parenterally 0-10 days after onset of stroke at least once and wherein the parenteral administration is followed by a period of enteral administration. In a preferred embodiment of the present invention, the deproteinised calf blood preparation is administered intravenously after onset of stroke once daily for a period of at the most 20 days, and the intravenous administration is followed by a period of oral administration of about 200 mg of the deproteinised calf blood preparation three times daily for a period of about 6 months or even longer as a substantially continuous treatment. In a preferred embodiment of the present invention, the deproteinised calf blood preparation is the medicament Actovegin®.
| |||||||||||
| 4. | US | 20130059842 - MANUFACTURING OF QUICK RELEASE PHARMACEUTICAL COMPOSITONS OF WATER INSOLUBLE DRUGS AND PHARMACEUTICAL COMPOSITIONS OBTAINED BY THE PROCESS OF THE INVENTION | 07.03.2013 |
| 13666278 | Nycomed Danmark ApS | Bertelsen Poul Egon | ||||
It has been found that pharmaceutical compositions comprising water insoluble drugs can be manufactured and formulated in a manner ensuring fast dissolution in gastric fluid. Advantageously, the manufacturing process provides a significantly improved stability, thus resulting in compositions that may have a longer shelf life than conventionally formulated and processed drugs. | |||||||||||
| 5. | ES | 2397380 - Procedimiento para preparar compuestos activos ópticamente puros | 06.03.2013 |
| 03782288 | NYCOMED GMBH | KOHL, Bernhard | ||||
|
| |||||||||||
| 6. | ES | 2397082 - Triazoloftalazinas como inhibidores de PDE2 | 04.03.2013 |
| 06700346 | NYCOMED GMBH | SCHMIDT, Beate | ||||
|
| |||||||||||
| 7. | ES | 2397080 - Triazoloftalazinas como agentes inhibidores de la PDE2 | 04.03.2013 |
| 06700240 | NYCOMED GMBH | SCHMIDT, Beate | ||||
|
| |||||||||||
| 8. | US | 08383611 - Ciclesonide containing aqueous pharmaceutical composition | 26.02.2013 |
| 10110632 | Nagano Atsuhiro | Nagano Atsuhiro | ||||
The present invention provides an aqueous pharmaceutical composition containing ciclesonide and hydroxypropyl-methylcellulose, wherein the ciclesonide is dispersed in an aqueous medium in the form of solid particles. The composition is able to avoid variations in the concentrations of ciclesonide during production as well as avoid decreases in the recovery rate of ciclesonide. | |||||||||||
| 9. | US | 20130045974 - NOVEL HYDROXY-6-HETEROARYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS | 21.02.2013 |
| 13661897 | NYCOMED GMBH | KAUTZ Ulrich | ||||
Compounds of the formula Ia*****
in which the substituents have the definitions provided in the specification, are novel, effective PDE4 inhibitors, useful in the treatment of psoriasis. | |||||||||||
| 10. | ES | 2396197 - Forma farmaceútica que contiene pantoprazol como ingrediente activo | 19.02.2013 |
| 10175417 | Nycomed GmbH | Dietrich, Rango | ||||
|
| |||||||||||
